The combination of Nivolumab and HuMax-IL8 (CXCL8 inhibitor) was tested in multiple cancers, including renal cell carcinoma (RCC), malignant melanoma, NSCLC, hepatocellular carcinoma (HCC), prostate carcinoma (PC), and squamous cell carcinoma of head and neck (SCCHN) (NCT04572451, NCT04123379, NCT03689699, NCT04848116). This evidence concerns the gene CXCL8 and hepatocellular carcinoma.